A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
Wissenschaftlicher Artikel
Authors
Baumann, K. H.
du Bois, A.
Meier, W.
Rau, J.
Wimberger, P.
Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfePublished in
Annals of Oncology ; 23 (2012), 9. - S. 2265-2271. - ISSN 0923-7534. - eISSN 1569-8041